Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel mitogen-activated protein kinase kinase inhibitors.

Expert opinion on investigational drugs - 1 Feb 2011

Chapman Mark S, Miner Jeffrey N

Abstract excerpt

INTRODUCTION: the development of new drugs over the last few decades has targeted specific proteins thought to be a key to the disease state. MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Genes, ras
Share to Inflammation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinase Kinases

Share to Molecular Targeted Therapy

Share to raf Kinases

Share to ras Proteins

Source

Identifiers

PMID: 21235429
DOI: 10.1517/13543784.2011.548803

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21235429-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel mitogen-activated protein kinase kinase inhibitors.PMID 21235429Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

MEK and the inhibitors: from bench to bedsideSemantic proximity Read ↗

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Semantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

Clinical experience of MEK inhibitors in cancer therapy.Semantic proximity Read ↗

The clinical development of MEK inhibitorsSemantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.